Sharma, RashmiSharma, Chaman Lal2007-04-142009-06-012007-04-142009-06-012007-04-14Sharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. Journal of Cancer Research and Therapeutics. 2007 Apr-Jun; 3(2): 92-5http://imsear.searo.who.int/handle/123456789/11138419 references.Gardasil is the first quadrivalent human papillomavirus (HPV)-types 6, 11, 16, 18 recombinant vaccine approved by the FDA on June 8, 2006. It induces genotype-specific virus-neutralizing antibodies and prevents infection with HPV. Various clinical trials demonstrated a reduction in the incidence of vaccine-type-specific persistent infections and of associated moderate- and high-grade cervical dysplasias and carcinomas in situ after its use. Gardasil is currently approved by FDA for prevention of genital warts, cancers and precancerous conditions of cervix and vulva in 9-26 year old females. Three doses of 0.5 ml of gardasil each at 0, 2 and 6 months are given intramuscularly. It is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine, patients with bleeding abnormalities or patients on anticoagulant therapy and during pregnancy. However, the vaccine, at an estimated $300-500 per course, is too expensive for many women in developing countries. Moreover, question regarding the longevity of the protection by vaccine is still unsolved. Hence, longer studies are required to establish its real status in cancer prevention.engAdultCancer Vaccines --adverse effectsCarcinoma --drug therapyClinical Trials as TopicFemaleHumansPapillomavirus Infections --drug therapyPapillomavirus Vaccines --adverse effectsPrevalenceUterine Cervical Neoplasms --drug therapyVaccines, Synthetic --adverse effectsJournal Article